|Articles|March 23, 2004

WCPM 2004 Brochure

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report

Your Questions Answered: The Biggest Pharma and Biotech Stories This Week

How New Therapies are Tackling Unmet Needs in IBD

Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq

WCPM 2004 Brochure

Related Content

Pharmaceutical Executive Daily: FDA Approves Zanvastro

FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults

Your Questions Answered: The Biggest Pharma and Biotech Stories This Week

The Limitations of JAK Inhibitors When Treating IBD

What's Next for Compounded Peptides: Q&A with Nate Hill

Trending on PharmExec

Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report

Your Questions Answered: The Biggest Pharma and Biotech Stories This Week

How New Therapies are Tackling Unmet Needs in IBD

Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial